Sanofi-Aventis said it was considering "strategic alternatives" for its U.S. dermatology business, as it seeks to refocus its business on growth areas such as diabetes and cancer treatments.
The company's comment came after Bloomberg News published a story on Wednesday on how Sanofi was seeking to sell the unit, which the report said could be valued around €300 million.
Sanofi has said previously that its dermatology business could come under review because it was too small. It does not disclose sales for the unit.
